Form 4: Vivani Medical's Chief Medical Officer, Lisa Porter, Reports Stock Option and RSU Grants

Lisa Porter, Chief Medical Officer of Vivani Medical, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Summary

• Lisa Porter, the Chief Medical Officer of Vivani Medical, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options for 80,000 shares of common stock at an exercise price of $1.03, vesting over four years.
• Additionally, 40,000 performance-based RSUs were granted, vesting in three stages based on the stock price reaching $3.15 for three consecutive days and continued service.
• The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months.
• If the RSUs fail to close at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants of stock options and RSUs are standard practice and align management's interests with shareholders. The performance-based vesting of RSUs is a positive incentive.

Positives

• The grant of stock options and RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
• The performance-based vesting of the RSUs incentivizes the achievement of a specific stock price target.

Risks

• The performance-based RSUs may expire if the stock price does not reach $3.15 within four years.
• The vesting of the stock options and RSUs is contingent upon the Reporting Person's continued service.

Future Outlook

The vesting of the RSUs is contingent on the stock price reaching $3.15 for three consecutive days within a four-year period, indicating a target for future stock performance.

Industry Context

Grants of stock options and RSUs are common practices in the pharmaceutical and biotech industries to incentivize key executives and align their interests with those of shareholders. The vesting schedules and performance-based conditions are designed to retain talent and drive company performance.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry.
• Vesting schedules, such as the one described (25% after one year, then monthly for 36 months), are typical.
• Performance-based RSUs, contingent on achieving specific stock price targets, are also common, aligning executive compensation with shareholder value creation.
• Comparable companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation plans.

Stakeholder Impact

• Shareholders: The grants align management's interests with shareholder value creation.
• Employees: The grants may have a positive impact on employee morale by demonstrating the company's commitment to its executives.

Key Dates

Keywords

Form 4, Vivani Medical, Stock Options, RSUs, Lisa Porter, Chief Medical Officer, Beneficial Ownership, Vesting